BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA ...
Revenue was $2.2 billion, an increase of 6.1% over the prior year, including organic growth of 5.5% Net income totaled $38.8 million, or $0.64 per diluted share, as compared to $43.6 million or $0.69 ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Pollard Banknote Limited (TSX: PBL) (“Pollard”) today released its financial results for the three months and year ended December 31, 2025. Full Year 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results